MedTech’s New Normal: More Regulatory, Pricing Pressures And Challenging Financing Climate
This article was originally published in The Gray Sheet
Executive SummarySustaining innovation in the current policy and financing environment may require new strategies from device companies focused not just on developing new products but on expanding into new kinds of offerings, including services and “holistic” solutions, Ernst & Young concludes in a recent report.
You may also be interested in...
Attorneys say Sarepta did not have an obligation to report its appeal, particularly since winning a formal dispute filing with the US FDA is a long shot.